"We are very pleased to have attracted three such highly skilled and regarded professionals to the Pharmalink Board," said Bengt Julander, Chairman of Pharmalink. "There are substantial milestones ahead. Our development programs on Nefecon(R), Xepol(R) and Busulipo(TM) have reached a stage of maturity when it is time to start pivotal trials and planning for commercialization. The new board members bring proven and highly relevant skills and experience in late phase product development, in business development and in sales and marketing."
"The new Board members' industry expertise will be invaluable as we develop our strategies to build the company in the coming years both through commercializing our existing portfolio and in expanding our pipeline," said Johan Haggblad, Managing Director of Pharmalink. "We also want to thank Anders Lonner and Jorgen Lonngren, who are leaving the Board, for their years of dedicated contributions and guidance."
Pharmalink AB is a privately held Swedish specialty pharma company that
develops proprietary pharmaceutical products in fields of unmet medical need.
Pharmalink has adopted a reformulation/repurposing strategy and has a vast
international network of physicians, biotech companies, CMOs, CROs and
specialist consultants. Pharmalink has a track record of introducing more
than 15 pharmaceutical products to market. Pharmalink currently has three
clinical phase development projects mature for out-licensing: Nefecon(R), an
effective treatment of IgA nephropathy; Xepol(R), the first effective
|SOURCE Pharmalink AB|
Copyright©2009 PR Newswire.
All rights reserved